RARE - Ultragenyx Pharmaceutical Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Novato,
United States
Type: Equity
RARE price evolution
RARE
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $480.69 | $112.25 | $213.58 | |
| Short term investments | $283.13 | $299.83 | $363.63 | |
| Net receivables | $93.3 | $105.98 | $100.25 | $73.39 |
| Inventory | $43.33 | $40.14 | $35.91 | $33.97 |
| Total current assets | $799.61 | $964.64 | $595.97 | $732.18 |
| Long term investments | $110.67 | $156.58 | $199.9 | |
| Property, plant & equipment | $272.45 | $278.71 | $285.11 | $290.57 |
| Goodwill & intangible assets | $210.65 | $209.45 | $210.68 | |
| Total noncurrent assets | $653.8 | $711.11 | $758.83 | |
| Total investments | $393.8 | $456.41 | $563.53 | |
| Total assets | $1538.36 | $1618.44 | $1307.08 | $1491.01 |
| Current liabilities | ||||
| Accounts payable | $35.99 | $59.81 | $40.97 | $42.11 |
| Deferred revenue | ||||
| Short long term debt | $11.72 | $12.78 | $12.6 | |
| Total current liabilities | $285.01 | $272.87 | $245.57 | $280.44 |
| Long term debt | $25.74 | $27.98 | $30.57 | |
| Total noncurrent liabilities | $913.15 | $921.24 | $935.16 | |
| Total debt | $37.46 | $40.76 | $43.17 | |
| Total liabilities | $1191.54 | $1186.02 | $1166.82 | $1215.6 |
| Shareholders' equity | ||||
| Retained earnings | -$3823.46 | -$3689.94 | -$3558.34 | -$3387.66 |
| Other shareholder equity | $1.38 | -$1.09 | -$0.43 | $0.65 |
| Total shareholder equity | $432.42 | $140.26 | $275.41 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $213.58 | $132.94 | $307.58 | $713.53 |
| Short term investments | $363.63 | $614.82 | $432.61 | $488.01 |
| Net receivables | $73.39 | $40.45 | $28.43 | $23.09 |
| Inventory | $33.97 | $26.77 | $16.23 | $13.05 |
| Total current assets | $732.18 | $883.9 | $856.6 | $1295.3 |
| Long term investments | $199.9 | $154.5 | $293.86 | $165.88 |
| Property, plant & equipment | $290.57 | $285.69 | $176.18 | $114.04 |
| Goodwill & intangible assets | $210.68 | $204.51 | $175.19 | $175.52 |
| Total noncurrent assets | $758.83 | $661.54 | $665.79 | $464.25 |
| Total investments | $563.53 | $769.32 | $726.47 | $653.89 |
| Total assets | $1491.01 | $1545.44 | $1522.4 | $1759.56 |
| Current liabilities | ||||
| Accounts payable | $42.11 | $43.27 | $17.14 | $12.92 |
| Deferred revenue | $1.48 | $9.08 | $66.57 | |
| Short long term debt | $12.6 | $11.78 | $11.07 | $8.98 |
| Total current liabilities | $280.44 | $261.21 | $181.37 | $189.61 |
| Long term debt | $30.57 | $19.81 | $30.9 | $39.25 |
| Total noncurrent liabilities | $935.16 | $931.74 | $418.47 | $415.57 |
| Total debt | $43.17 | $31.59 | $41.97 | $48.23 |
| Total liabilities | $1215.6 | $1192.95 | $599.84 | $605.18 |
| Shareholders' equity | ||||
| Retained earnings | -$3387.66 | -$2781.02 | -$2073.6 | -$1619.58 |
| Other shareholder equity | $0.65 | -$0.84 | -$1.4 | $0.69 |
| Total shareholder equity | $275.41 | $352.49 | $922.56 | $1154.38 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $139.49 | $147.03 | $108.83 | $127.39 |
| Cost of revenue | $21.28 | $17.53 | ||
| Gross Profit | $118.47 | $125.75 | $91.3 | $115.34 |
| Operating activities | ||||
| Research & development | $161.5 | $178.49 | ||
| Selling, general & administrative | $80.6 | $78.16 | ||
| Total operating expenses | $250.46 | $243.94 | $256.65 | $237.39 |
| Operating income | -$118.19 | -$165.35 | ||
| Income from continuing operations | ||||
| EBIT | -$130.74 | -$170.23 | ||
| Income tax expense | $0.3 | $0.86 | $0.46 | -$3.7 |
| Interest expense | $11.41 | $1.89 | ||
| Net income | ||||
| Net income | -$133.52 | -$131.6 | -$170.68 | -$123.19 |
| Income (for common shares) | -$131.6 | -$170.68 | ||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $434.25 | $363.33 | $351.41 | $271.03 |
| Cost of revenue | $28.32 | $16.01 | $6.13 | |
| Gross Profit | $389.04 | $335.01 | $335.4 | $264.9 |
| Operating activities | ||||
| Research & development | $705.79 | $497.15 | $412.08 | |
| Selling, general & administrative | $278.14 | $219.98 | $182.93 | |
| Total operating expenses | $958.25 | $983.93 | $717.13 | $595.02 |
| Operating income | -$648.92 | -$381.74 | -$330.12 | |
| Income from continuing operations | ||||
| EBIT | -$701.73 | -$452.98 | -$185.36 | |
| Income tax expense | -$1.82 | $5.7 | $1.04 | $1.21 |
| Interest expense | $0.4 | |||
| Net income | ||||
| Net income | -$606.64 | -$707.42 | -$454.02 | -$186.57 |
| Income (for common shares) | -$707.42 | -$454.02 | -$186.57 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$131.6 | -$170.68 | -$123.19 | |
| Operating activities | ||||
| Depreciation | $8.86 | $8.85 | $8.22 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $39.37 | $36.93 | $33.74 | |
| Total cash flows from operations | -$76.96 | -$190.73 | -$83.9 | |
| Investing activities | ||||
| Capital expenditures | -$2.01 | -$3.21 | -$1.6 | |
| Investments | $65.11 | $109.71 | -$105.15 | |
| Total cash flows from investing | -$120.5 | $60.56 | $94.44 | -$107.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $384.94 | -$0.06 | $330.61 | |
| Net borrowings | ||||
| Total cash flows from financing | $396.06 | $384.94 | -$0.06 | $330.61 |
| Effect of exchange rate | -$0.05 | -$0.65 | -$0.68 | $1.1 |
| Change in cash and equivalents | -$59.18 | $367.89 | -$97.03 | $140.79 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$606.64 | -$707.42 | -$454.02 | -$186.57 |
| Operating activities | ||||
| Depreciation | $26.01 | $18.22 | $13.24 | $12.26 |
| Business acquisitions & disposals | -$75.03 | |||
| Stock-based compensation | $135.23 | $130.38 | $104.95 | $85.73 |
| Total cash flows from operations | -$474.81 | -$380.46 | -$338.69 | -$132.22 |
| Investing activities | ||||
| Capital expenditures | -$44.27 | -$116.12 | -$73.09 | -$43.91 |
| Investments | $219.81 | -$69.66 | -$121.34 | -$129.66 |
| Total cash flows from investing | $168 | -$291.65 | -$195.37 | -$179.12 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $388.17 | $10.81 | $119.04 | $600.51 |
| Net borrowings | ||||
| Total cash flows from financing | $388.14 | $501.21 | $118.55 | $600.27 |
| Effect of exchange rate | $0.46 | -$1.07 | -$1.19 | $1.12 |
| Change in cash and equivalents | $81.8 | -$171.98 | -$416.71 | $290.05 |
News
Fundamentals
| Market cap | $4.25B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 92.30M |
| Revenue | $522.75M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$558.99M |
| Revenue Q/Q | 42.27% |
| Revenue Y/Y | 27.44% |
| P/E ratio | -7.60 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 8.13 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$6.06 |
|---|---|
| ROA | -37.55% |
| ROE | N/A |
| Debt/Equity | 4.41 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.81 |
| Quick ratio | 2.65 |